Science 37® Reveals a Pivotal Shift in the Clinical Trials Landscape
November 17 2021 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37”), pioneer of
decentralization and Operating System for today’s more agile
clinical trials™, has published new data suggesting that the
clinical research industry has reached a pivotal shift in the way
that clinical trials are conducted, as Sponsors and CROs report
they plan to run more agile (or hybrid) clinical trials in 2022
than traditional, site-based studies.
Findings are the result of a sentiment
study among 127 senior clinical research executives in September
and October 2021. Nearly eight of 10 respondents said they plan to
run an agile clinical trial in the next 12 months. Conversely, just
seven of 10 said they are planning to run a traditional, site-based
study in the next 12 months.
“The power of increased decentralization is becoming undeniable
as more sponsors benefit from faster enrollment, greater retention
and increased diversity,” said David Coman, Chief Executive Officer
at Science 37. “Leveraging the Science 37 Operating System, our
customers are enabling much more agile clinical trial designs that
realize these benefits while significantly reducing patient burden
and delivering more universal access for patients and providers,
anywhere.”
In addition to documenting this
fundamental shift, the survey data also paints a vivid picture of
the decentralized clinical trial (DCT) landscape for the year
ahead, suggesting significant increases in DCT activity across
multiple therapeutic areas and study phases. Among the
findings:
- 46% of respondents expect to run an oncology study utilizing
DCT in the next year, vs. 35% for the previous year—making oncology
the most prevalent DCT category.
- Oncology, CNS, rare diseases, and immunology should see the
biggest uptake in DCT use.
- The report suggests significant increases in DCT activity
across Phase II, III, and IV studies.
- We also expect to see big increases in the deployment of most
individual DCT components, particularly eConsent, telemedicine,
mobile nurses, and remote sites in a hybrid model.
- The top-3 perceived benefits of DCT are better patient
experience, better patient retention, and faster recruitment.
- The top-3 perceived challenges of DCT are integrating
traditional sites with DCT, lack of in-house capabilities, and
regulatory concerns.
You can download a copy of the full report for free at
www.science37.com.
About Science 37Science 37 Holdings, Inc.
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 Clinical Trial Operating System
(OS) supports today’s more agile clinical research designs with its
full stack, end-to-end technology platform and specialized networks
of patient communities, telemedicine investigators, mobile nurses,
remote coordinators and connected devices. Configurable to enable
any study type, the Science 37 OS enables up to 15x faster
enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com. About the
Agile Clinical Trial™: Use of decentralized tools and
methodologies is increasing. With these advances, patients will be
able to participate from their home, a site, or a combination of
home and site; and providers will be able to participate on or
off-premise. This symbiotic clinical trial or the “agile clinical
trial” requires: The ability to activate any provider and any
patient, regardless of premises; a network of patient communities,
telemedicine investigators, mobile nurses, and remote
coordinators—all with a flexible Operating System to seamlessly
navigate between on-site and
off-site.
MEDIA INQUIRIES:Margie KoomanVP, Marketing
& Communications, Science 37Margie.Kooman@science37.com Science
37984.377.3737
INVESTOR RELATIONS:Caroline PaulGilmartin
Groupinvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024